Compare · MDLN vs TMCI
MDLN vs TMCI
Side-by-side comparison of Medline Inc. (MDLN) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 193.9x TMCI ($229.0M).
- Over the past year, MDLN is down 17.1% and TMCI is down 40.1% - MDLN leads by 23.0 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 9 for TMCI).
- MDLN has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- Medline Inc.
- Treace Medical Concepts Inc.
- Price
- $33.80+0.58%
- $3.53+0.57%
- Market cap
- $44.40B
- $229.0M
- 1M return
- -19.55%
- +82.90%
- 1Y return
- -17.07%
- -40.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 20
- 9
- Recent ratings
- 25
- 19
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest TMCI
- Chief Executive Officer Treace John T. bought $177,915 worth of shares (50,000 units at $3.56), increasing direct ownership by 0.69% to 7,323,833 units (SEC Form 4)
- Chief Executive Officer Treace John T. bought $340,589 worth of shares (115,520 units at $2.95), increasing direct ownership by 2% to 7,273,833 units (SEC Form 4)
- Treace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Jain Deepti was granted 30,000 shares, increasing direct ownership by 43% to 100,243 units (SEC Form 4)
- Director Bakewell John K was granted 30,000 shares, increasing direct ownership by 17% to 204,056 units (SEC Form 4)
- Director Kiernan Jane E was granted 30,000 shares, increasing direct ownership by 47% to 93,949 units (SEC Form 4)
- Director Berry Lance A was granted 30,000 shares, increasing direct ownership by 67% to 74,593 units (SEC Form 4)
- Director Hanna Betsy was granted 30,000 shares, increasing direct ownership by 66% to 75,243 units (SEC Form 4)
- Director Hamilton Lawrence W was granted 30,000 shares, increasing direct ownership by 68% to 74,056 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.